Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 1997

View Archived Issues

MMP inhibitors described by Agouron

New spironolactone formulation imparts improved bioavailability, clinical response

Crinone approved in Mexico

Generic levobunolol approved in Canada

High rating given to Saliva Diagnostic Systems' SeroStrip HIV

Organon's fertility hormone approved in Canada

Viragen opens manufacturing plant for alfa interferon

FDA approves IND for cystic fibrosis drug

Angiotech signs license agreement with Boston Scientific and Cook

Elan licenses Morphelan to Targon Corporation

Efficacy shown with roxithromycin for cardiovascular disease

The National Psoriasis Foundation warns of potential danger of OTC psoriasis product

Trovert receives Orphan Drug designation for acromegaly

P&U antioxidant shows cerebroprotective activity in rats

Alkermes issued U.S. patent for ProLease

YM90K efficacy shown in rat model of cerebral ischemia

Endothelin antagonists for cerebral ischemia

Bradykinin antagonist shows potential in stroke and ischemic disorders

NR2B-selective NMDA antagonist for occlusive stroke

YM-872 shows potential for stroke in animal models

Antiischemic activity of calmodulin antagonist reported

Medtronic Jewel AF enters clinical trials in U.S.

HIV/AIDS research contract granted to Population Council

Secreted proteins strategic alliance between Genset and Genetics Institute

AmBisome cleared by FDA

Taxotere cleared in four additional countries

Teva's problems with clindamycin

Antiinflammatory drugs in early development at Searle

Arginine mimetics from Boehringer Mannheim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...